Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Eli Lilly and Company Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00125892 |
This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.
Condition | Intervention | Phase |
---|---|---|
Fibromyalgia |
Drug: duloxetine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome |
Estimated Enrollment: | 320 |
Study Start Date: | July 2005 |
Study Completion Date: | March 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 9075, F1J-MC-HMEH |
Study First Received: | July 29, 2005 |
Last Updated: | May 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00125892 |
Health Authority: | United States: Food and Drug Administration |
Dopamine Muscular Diseases Neuromuscular Diseases Musculoskeletal Diseases Myofascial Pain Syndromes |
Fibromyalgia Pain Rheumatic Diseases Serotonin Duloxetine |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Nervous System Diseases Physiological Effects of Drugs |
Psychotropic Drugs Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents Antidepressive Agents |